Search results
Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for generalized anxiety disorder.2. How about you all running this company come up with a plan to give me back my shares you took. So pissed about that.
- Psychedelics In Minnesota
Gov Walz Authorizes Task Force & Safe Consumption Sites Via...
- Contested Solicitation
The Real Housewives of Atlanta; The Bachelor; Sister Wives;...
- Psychedelics In Minnesota
The milestones MNMD has achieved have DERISKED MNMD from a penny stock to a small cap biotech company with a very large drug portfolio and numerous future catalysts. I do not expect to make 10x my investment in a week, nor should you. Is there still tremendous upside even at the current valuation of ~$1.5bn?
People also ask
Is mnmd still a good investment?
Why has mnmd grown so much?
Is mnmd a risky investment?
Is mnmd a good investment for early stage biotech?
The milestones MNMD has achieved have DERISKED MNMD from a penny stock to a small cap biotech company with a very large drug portfolio and numerous future catalysts. I do not expect to make 10x my investment in a week, nor should you. Is there still tremendous upside even at the current valuation of ~$1.5bn?
Here’s what I get, legit just mindmed stuff. Googles algorithm is finnicky, I guarantee they are not trying to suppress a small cap biotech stock. Mnmd is currently my second largest position in my stock portfolio, I love the company, but I can’t get behind some crackpot theory.
Just wanted to note a release this morning indicating the MMED board has received a value enhancement proposal (suggesting it pursue cost reduction & focus on core drugs)- from a <6% shareholder FCM LLC (managed by Dr Scott Freeman, former CMO).
MNMD and other MDMA stocks. With MDMA's FDA approval most likely the end of 2021, I think MNMD is a solid buy both short and long term. I am very bullish on the entire medical psychedelic industry. We currently have Ketamine clinics in FL that are booming and work great for PTSD and Depression.
Main objectives are: a) Nasdaq would delist MNMD if it didn't get its share price above $1. b) Many institutional investors (pension funds, hedge funds, etc.) are not allowed (based on their agreements with their own investors) to buy stocks that are below $1, or sometimes below $5.
